Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $90.00

Halozyme Therapeutics (NASDAQ:HALO) had its price objective increased by HC Wainwright from $85.00 to $90.00 in a report published on Thursday morning,Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock.

Other equities analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, September 5th. JMP Securities lifted their target price on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the company a “market outperform” rating in a research note on Wednesday, August 6th. The Goldman Sachs Group began coverage on shares of Halozyme Therapeutics in a report on Thursday, July 10th. They issued a “neutral” rating and a $55.00 target price for the company. JPMorgan Chase & Co. raised their price target on Halozyme Therapeutics from $60.00 to $63.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. Finally, Benchmark upped their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $70.44.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $68.98 on Thursday. The stock has a market cap of $8.07 billion, a P/E ratio of 15.78, a P/E/G ratio of 0.38 and a beta of 1.16. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. The stock’s fifty day moving average is $70.45 and its 200 day moving average is $61.95. Halozyme Therapeutics has a one year low of $42.01 and a one year high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The business had revenue of $325.72 million during the quarter, compared to analysts’ expectations of $282.66 million. During the same quarter in the prior year, the business posted $0.91 earnings per share. The business’s quarterly revenue was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Sell-side analysts anticipate that Halozyme Therapeutics will post 4.73 earnings per share for the current year.

Insider Activity

In other news, Director Bernadette Connaughton sold 4,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $73.68, for a total value of $294,720.00. Following the sale, the director directly owned 46,952 shares in the company, valued at approximately $3,459,423.36. This represents a 7.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $75.35, for a total value of $1,507,000.00. Following the transaction, the chief executive officer owned 733,719 shares of the company’s stock, valued at approximately $55,285,726.65. The trade was a 2.65% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 128,227 shares of company stock valued at $8,908,195. 2.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Isthmus Partners LLC boosted its position in Halozyme Therapeutics by 2.5% in the 1st quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company’s stock valued at $439,000 after buying an additional 169 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 174 shares during the period. OneDigital Investment Advisors LLC grew its stake in Halozyme Therapeutics by 1.7% in the first quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company’s stock worth $649,000 after purchasing an additional 175 shares in the last quarter. Park Place Capital Corp increased its holdings in Halozyme Therapeutics by 20.1% during the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 182 shares during the period. Finally, Xponance Inc. raised its position in Halozyme Therapeutics by 1.1% during the 1st quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company’s stock valued at $1,190,000 after purchasing an additional 198 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.